|Mr. Paul R. Perreault BA Psychology||CEO, MD & Exec. Director||N/A||N/A||60|
|Mr. David Mark Lamont ACA, BCom||Chief Financial Officer||1.85M||N/A||51|
|Dr. Andrew Cuthbertson BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO||Chief Scientific officer & Director of R&D||N/A||N/A||62|
|Mr. Gregory Boss J.D., BS(Hon)||Exec. VP of Legal & Group Gen. Counsel||N/A||N/A||56|
|Ms. Laurie Reed BS (Finance), MS (Organizational Development)||Sr. VP of HR||N/A||N/A||53|
CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiencys, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.
CSL Limited’s ISS Governance QualityScore as of September 1, 2017 is 6. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 10.